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bust to changes of most parameters—most sensitive to
prevalence and eradication efficacy changes.
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SICKNESS FUNDS DM 2.8 BILLION PER YEAR
Schultes HJ1, Guminski W2, Rosche U2, Ries B1, Pirk O3
1Novartis Pharma, Nuremberg, Germany; 2IG 
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BACKGROUND: With a prevalence of up to 20%, Irri-
table Bowel Syndrome (IBS) could cost the German Sick-
ness Funds (GKV) more than DM 28 billion (10,5% of
its total expenditures) per year. Despite these potentially
tremendous costs it is still a fairly obscure disease in
terms of proper diagnosis and lacking effective treatment.
OBJECTIVE: To assess diagnosis and treatment options
of IBS using strict Rome-II criteria. METHODS: Face-to-
face interviews of patients (121) and physicians (147
GPs, 53 internists). RESULTS: The patient survey (age
14–74 yrs.; strict Rome-II criteria) puts the prevalence of
IBS (constipated and alternating type) in Germany at
around 2.3% (1.4 million). This figure correlates well
with previous findings. The patients responded that they
experienced an average of 7 episodes per year, each last-
ing about 4–5 days. Some 11% of them suffer perma-
nently. Of the physicians questioned, only 73% recognize
IBS when given the symptoms; 57% of these actually
classify it accordingly while an alternative diagnosis is
“irritable colon” (24%). When choosing a drug, daily
treatment costs outweigh every other factor of the physi-
cians relevant set (efficacy, onset, side-effects, mode of
action etc.) by about 3:1. In consequence a drug treat-
ment is initiated in (only) 40% of the cases. This is also
due to a lack of effective and specific treatment which
could help to reduce the frequency of episodes. Results of
another study put the direct costs of the average IBS pa-
tient at around DM 1,729 per year. Combining this with
the above findings results in a more realistic figure of
around DM 988 million in direct costs per year (0.37%
of total GKV expenditures). CONCLUSION: These com-
parably high costs (insulin treated diabetes: DM 1,217
p.a.) could be significantly reduced by DM 247 for each
episode prevented through proper diagnosis and conse-
quent treatment with a specific and effective medication.
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OBJECTIVES: The objective was to describe the disease
state (DS) transition patterns of gastroesophageal reflux
disease (GERD) by applying a multi-state model assum-
ing a Markov process. METHODS: This retrospective
study utilized administrative claims for subjects with
GERD from a large Midwest USA health care plan. Sub-
jects were tracked for six, six-month time periods (base-
line and five followups). Within each time period, ICD-9
diagnosis codes were used to categorize subjects’ GERD
into four DS plus a non-symptomatic state: DS0 {no
GERD diagnosis}, DS1 {mild esophagitis}, DS2 {reflux
esophagitis}, DS3 {esophageal ulceration}, and DS4 {stric-
tures and complications}. GERD transition probabilities
and patterns were analyzed in a five-state Markov frame-
work. Disease regressions and progressions were al-
lowed. The effects of patient and provider covariables on
transition probabilities were modeled using logistic re-
gression techniques. RESULTS: A total of 7575 subjects
with GERD were analyzed. In the five followup periods
combined, 79% of the subjects were in GERD DS0, 6%
in DS1, 8% in DS2, 2% in DS3, and 5% in DS4. For all
initial DS, the most frequent transition path was to re-
gress to DS0 (becoming non-symptomatic) and the sec-
ond most common was to stay in the initial disease state.
For subjects ending a time period in DS1, 89% regressed
to DS0 in the next time period, while 6% stayed in DS1,
3% progressed to DS2, 1% progressed to DS3, and 1%
progressed to DS4. Multivariate modeling of risk factors
influencing transitions showed that progressing from
DS1 is associated with age 70, a proton pump inhibitor
prescription, and absence of a diagnostic procedure.
CONCLUSIONS: The Markov analysis showed that sub-
jects with GERD commonly have their symptoms regress,
with only a small percent progressing. The Markov
model is a useful methodology to research disease states
in a retrospective database setting within a health care
plan.
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OBJECTIVES: Approximately one-half of the American
population experiences weekly symptoms of gastroesoph-
ageal reflux disease (GERD). With the hypothesis that
not all patients are completely symptom free on proton
pump inhibitor’s (PPI’s), the pharmaceutical industry is
formulating more potent anti-secretory drug therapies. In
November of 2000 the FDA approved esomeprazole for
the treatment of Erosive Esophagitis (EE). Esomeprazole
is a more potent inhibitor of gastrin and gastric acid,
with clinical studies demonstrating quicker symptom re-
lief with more complete 24-hour acid control. If complete
acid control translates into better long-term symptom re-
lief for chronic symptomatic GERD it may play a vital
126 Abstracts
role in refractory GERD patients. The purpose of this
cross-sectional survey study is to estimate the percentage
of patients actively treated with PPI’s (omeprazole and
lansoprazole), who perceive control of their symptoms.
The Gastrointestinal Symptom Rating Scale (GSRS), a
validated rating scale to assess GERD patients’ quality of
life, was utilized. The study hypothesis is that 80% of the
patients will perceive their symptom control is very good
or excellent. METHODS: An unblinded self-adminis-
tered questionnaire, including the GSRS, was mailed to
300 patients who were currently receiving GERD mainte-
nance therapy with a PPI. Patients were asked questions
regarding the duration and severity of symptoms, dosing
of medication, contributing lifestyle factors and debilita-
tion of disease. RESULTS: 153 questionnaires were re-
turned fully completed, a 51% response rate. The sur-
veyed patients were 60  14 years with 89% of
respondents being male. Of the PPI’s prescribed 86% and
14% were lansoprazole and omeprazole respectively. The
median total score of the GSRS was 19, representing mild
to moderate patient symptomatology. CONCLUSIONS:
66% of respondents treated with currently prescribed
PPI’s had very good or excellent symptom control, how-
ever the need exists for a more effective PPI for adequate
symptom control in 34% of patients.
PGI13
FACTORS ASSOCIATED WITH PHYSICIAN 
KNOWLEDGE OF WHETHER PRESCRIPTION 
DRUGS ARE ON FORMULARY
Shih YCT1, Sleath B2
1MEDTAP International, Bethesda, MD, USA; 2School of 
Pharmacy, University of North Carolina at Chapel Hill,
Chapel Hill, NC, USA
OBJECTIVE: Prescription drug formularies have been
used by many pharmacy benefit managers (PBMs) as a
tool to control the rising costs of prescription drugs and
became increasingly popular since the 1990s. Despite its
popularity, little is known about how familiar physicians
are with what prescriptions are on formulary. This study
examines factors associated with physician knowledge of
formulary. METHODS: The National Ambulatory Med-
ical Care Survey (NAMCS) is a data series of annual sur-
vey of a national representative sample of physician of-
fice visits. It provides up to six medications associated
with each office visit. The 1998 NAMCS collected infor-
mation regarding the formulary status (yes, no, do not
know, or not applicable) of each medication and pro-
vided a unique opportunities to assess physicians’ knowl-
edge of formulary. Univariate analyses as well as multi-
variate logit model were used to examine the association
between physician knowledge of formulary and types of
visits, physician specialty and practice locations. RE-
SULTS: On average, 47% of physicians did not know
whether the drug they prescribed was on formulary. Phy-
sicians whose patients belonged to an HMO and were
paid by capitation were seven times more likely to know
whether a drug was on formulary, compared to those
whose patients were neither in an HMO nor capitated.
Physicians in the South were 1.7 times more likely to
know than those in the West, whereas the odd-ratios was
0.7 for those in the Midwest. Neither physician specialty
(primary care physician versus specialist) nor patient his-
tory (new versus established patient) was found to be sig-
nificantly associated with physician knowledge of formu-
lary. CONCLUSIONS: It is important for PBMs to find
mechanisms to increase physician awareness of whether a
patient’s medications are on formulary. Improving physi-
cians’ understanding of what medications were on for-
mulary could potentially decrease prescription drug costs
for health care plans and patients.
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OBJECTIVES: To assess the association between hospi-
tal costs and the appropriateness of empirical antibiotic
treatment for community-acquired intra-abdominal in-
fection. METHODS: Patients were identified from hospi-
tal discharges from three hospitals for 1993 to 1997.
Medical records were obtained to validate the diagnosis
and obtain details of antibiotic therapy and its outcome.
Valid cases had macroscopic evidence of intra-abdominal
infection at operation, therefore all cases had surgical
control of infection in addition to antimicrobial therapy.
Appropriateness of empirical therapy was assessed from
the results of in-vitro sensitivity tests (culture positive
cases) and compliance with local antibiotic policies (cul-
ture negative cases). RESULTS: We identified 294 valid
cases of intra-abdominal infection of whom 162 (55%)
were culture positive. Appropriate antibiotic treatment
was associated with significantly shorter length of stay
and lower investigation costs for patients with positive
cultures but not for patients with negative cultures or no
test/result (data not shown). Culture ve cases, appropri-
ate (n  129) vs inappropriate (n  33): mean length of
stay 12 vs 22 days, p  0.0007 boot strap t test, mean in-
vestigation cost £250 vs £409 p  0.04, mean antibiotic
cost £138 vs £128 p  0.9. A log transformed linear re-
gression analysis was carried out on the cost data for the
culture positive cases adjusting for five independent vari-
ables. Inappropriate antibiotics, increasing age and a
higher number of comorbidities and previous admissions
were significantly associated with increased cost of hospi-
tal stay but not gender. This model accounted for 34% of
the variance in cost of hospital stay. For the cost of inves-
tigations inappropriate treatment, increasing age and
